CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV

Nanoparticles are playing an increasingly powerful role in vaccine development. Here, we report the repurposing of nonstructural proteins 10 and 11 (hereafter NSP10) from the replicase polyprotein 1a (pp1a) of the human SARS coronavirus (severe acute respiratory syndrome) as a novel self-assembling platform for bioengineered nanoparticles for a variety of applications including vaccines. NSP10 represents a 152 amino acid, 17 kD zinc finger transcription/regulatory protein which self-assembles to form a spherical 84 Å diameter nanoparticle with dodecahedral trigonal 32 point symmetry. As a self-assembling nanoparticle, NSP10 possesses numerous advantages in vaccine development and antigen display, including the unusual particle surface disposition of both the N- and C-termini. Each set of N- or C-termini is spatially disposed in a tetrahedral arrangement and positioned at optimal distances from the 3-fold axes (8-10 Å) to nucleate and stabilize the correct folding of complex helical or fibrous trimeric receptors, such as those responsible for viral tropism and cell infection. An application example in the exploratory development of a therapeutic vaccine for idiopathic pulmonary fibrosis (IPF), including preliminary analysis and immunogenic properties, is presented. The use of this system could accelerate the discovery and development of vaccines for a number of human, livestock, and veterinary applications.

Download Full-text

Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles

Vaccine ◽

10.1016/j.vaccine.2021.04.035 ◽

2021 ◽

Author(s):

Saori Ito ◽

Jutaro Nakamura ◽

Michiko Fukuta ◽

Takehiro Ura ◽

Takeshi Teshigawara ◽

...

Keyword(s):

Pseudomonas Aeruginosa ◽

Therapeutic Vaccine ◽

Membrane Vesicles ◽

Bacterial Membrane

Download Full-text

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches

Scientific Reports ◽

10.1038/s41598-021-91997-4 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Samira Sanami ◽

Fatemeh Azadegan-Dehkordi ◽

Mahmoud Rafieian-Kopaei ◽

Majid Salehi ◽

Maryam Ghasemi-Dehnoo ◽

...

Keyword(s):

Cervical Cancer ◽

T Lymphocytes ◽

Tertiary Structure ◽

Therapeutic Vaccine ◽

Epitope Prediction ◽

Therapeutic Effects ◽

Epitope Vaccine ◽

In Vivo Experiments

AbstractCervical cancer, caused by human papillomavirus (HPV), is the fourth most common type of cancer among women worldwide. While HPV prophylactic vaccines are available, they have no therapeutic effects and do not clear up existing infections. This study aims to design a therapeutic vaccine against cervical cancer using reverse vaccinology. In this study, the E6 and E7 oncoproteins from HPV16 were chosen as the target antigens for epitope prediction. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) epitopes were predicted, and the best epitopes were selected based on antigenicity, allergenicity, and toxicity. The final vaccine construct was composed of the selected epitopes, along with the appropriate adjuvant and linkers. The multi-epitope vaccine was evaluated in terms of physicochemical properties, antigenicity, and allergenicity. The tertiary structure of the vaccine construct was predicted. Furthermore, several analyses were also carried out, including molecular docking, molecular dynamics (MD) simulation, and in silico cloning of the vaccine construct. The results showed that the final proposed vaccine could be considered an effective therapeutic vaccine for HPV; however, in vitro and in vivo experiments are required to validate the efficacy of this vaccine candidate.

Download Full-text